Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Current Deferred Revenue (2024 - 2025)

Historic Current Deferred Revenue for Nuvation Bio (NUVB) over the last 2 years, with Q3 2025 value amounting to $9.1 million.

  • Nuvation Bio's Current Deferred Revenue fell 2968.63% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.1 million, marking a year-over-year decrease of 2968.63%. This contributed to the annual value of $11.1 million for FY2024, which is N/A changed from last year.
  • Nuvation Bio's Current Deferred Revenue amounted to $9.1 million in Q3 2025, which was down 2968.63% from $9.7 million recorded in Q2 2025.
  • Over the past 5 years, Nuvation Bio's Current Deferred Revenue peaked at $12.9 million during Q3 2024, and registered a low of $9.1 million during Q3 2025.